表紙:インターロイキン-7受容体サブユニットアルファ - パイプライン分析
市場調査レポート
商品コード
949884

インターロイキン-7受容体サブユニットアルファ - パイプライン分析

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drugs In Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 65 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
インターロイキン-7受容体サブユニットアルファ - パイプライン分析
出版日: 2021年12月30日
発行: Global Markets Direct
ページ情報: 英文 65 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) を標的とした治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

目次

表のリスト

図のリスト

  • イントロダクション
  • 調査範囲
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 概要
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 治療薬の開発
  • 開発中の製品:開発段階別
  • 開発中の製品:治療分野別
  • 開発中の製品:適応症別
  • 開発中の製品:企業別
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 治療薬の評価
  • 評価:作用機序別
  • 評価:投与経路別
  • 評価:分子タイプ別
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 治療薬開発に従事している企業
  • Allterum Therapeutics LLC
  • Genexine Inc
  • OSE Immunotherapeutics
  • RevImmune SAS
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 薬剤プロファイル
  • CYT-107 - 薬剤プロファイル
  • 製品説明
  • 作用機序
  • R&Dの進捗状況
  • efineptakin alfa - 薬剤プロファイル
  • 製品説明
  • 作用機序
  • R&Dの進捗状況
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 休止中のプロジェクト
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 開発が中止された製品
  • インターロイキン-7受容体サブユニットアルファ (CDw127/CD127/IL7R) - 製品開発のマイルストーン
  • 最新ニュースとプレスリリース
  • 付録
  • 調査手法
  • 調査範囲
  • 2次調査
  • 1次調査
  • 専門家パネル検証
  • 連絡先
  • 免責事項
図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Allterum Therapeutics LLC, 2021
  • Pipeline by Genexine Inc, 2021
  • Pipeline by Medikine Inc, 2021
  • Pipeline by OSE Immunotherapeutics, 2021
  • Pipeline by RevImmune SAS, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
目次
Product Code: GMDHC3036TDB

Summary:

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin 7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis, and juvenile idiopathic arthritis.

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase II and Preclinical stages are 3 and 3 respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal, Hematological Disorders, Immunology, Toxicology and Women's Health which include indications Coronavirus Disease 2019 (COVID-19), Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Breast Cancer, Cervical Intraepithelial Neoplasia (CIN), Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus Infections, Hypopharyngeal Cancer, Idiopathic CD4 Lymphocytopenia, Kaposi Sarcoma, Laryngeal Cancer, Lymphocytopenia, Malignant Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Mycobacterium avium Infections, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Progressive Multifocal Leukoencephalopathy, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sepsis, Sezary Syndrome, Sicca Syndrome (Sjogren), Small-Cell Lung Cancer, Solid Tumor, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Ulcerative Colitis and Unspecified Cancer.

The latest report Interleukin 7 Receptor Subunit Alpha - Drugs In Development, 2021, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
  • The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Overview
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies Involved in Therapeutics Development
  • Allterum Therapeutics LLC
  • Genexine Inc
  • Medikine Inc
  • OSE Immunotherapeutics
  • RevImmune SAS
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Products
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued Products
  • Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer